PsiOxus is committed to develop our pipeline through the establishment of strategic partnerships with leading immuno-oncology companies and academic groups. We are currently seeking strategic immuno-oncology partners for next generation oncolytic virus products from our proprietary T-SIGn platform technology, including:

  • Out-license of PsiOxus novel T-SIGn preclinical products
  • Research collaborations to develop novel virus programs
  • Research collaborations to develop programs using proprietary partner transgene combinations

For more information or inquiries on collaborations and partnerships, please contact

Strategic Collaborations

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image